
Mendus - ADVANCE II survival data confirms positive MRD results

Redeye comments on Mendus presenting ADVANCE II survival data at ASH 2022. The study had not yet reached median relapse-free survival after a median c19.4 months follow-up, indicating considerably better mRFS than historical QUAZAR AML-001 controls. We increase our estimated likelihood of approval for DCP-001 and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Mendus - ADVANCE II survival data confirms positive MRD results](#)